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Abstract: 
Obscurin, a giant modular cytoskeletal protein, is comprised mostly of tandem 
immunoglobulin-like (Ig-like) domains.  This architecture allows obscurin to connect distal 
targets within the cell.  The linkers connecting the Ig domains are usually short (3-4 
residues). The physical effect arising from these short linkers is not known; such linkers 
may lead to a stiff elongated molecule or, conversely, may lead to a more compact and 
dynamic structure.  In an effort to better understand how linkers affect obscurin flexibility, 
and to better understand the physical underpinnings of this flexibility, here we study the 
structure and dynamics of four representative sets of dual obscurin Ig domains using 
experimental and computational techniques.  We find in all cases tested, tandem obscurin 
Ig domains interact at the poles of each domain and tend to stay relatively extended in 
solution.  NMR, SAXS and MD simulations reveal that while tandem domains are 
elongated, they also bend and flex significantly.  By applying this behavior to a simplified 
model, it becomes apparent obscurin can link targets more than 200 nm away.  However, 
as targets get further apart, obscurin begins acting as a spring, and requires progressively 
more energy to further elongate. 
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Chapter 1 
Background: 
Obscurin is an extremely large (~970 kDa) human protein.1  Proteins are biological 
macromolecules that perform tasks inside of cells:  think of them as biological nanobots.  
Proteins are long linear polymers of amino acids, which fold and contort into unique 
shapes that dictate their function.  Obscurin is a cytoskeletal protein, which means it 
functions as scaffolding or structural support in cells.  Obscurin is found in both muscle 
cells and epithelial (skin, breast tissue, intestinal linings, etc.) cells of humans, and is 
made up of multiple domains (parts of proteins that are able to function normally when 
isolated from the rest of the protein) linked together.2  This molecular structure is similar 
to that of a long train (Figure 1-1)3: each domain is a train car, and the linker between the 
cars is slightly flexible. 
The purpose of the work 
described in this thesis is to 
determine how obscurin behaves 
in the cell by analyzing its flexibility.  
Due to its structure and function, 
we expect obscurin to also behave 
as a force resistor in cells.4  Other 
known cytoskeletal force resistors 
are similar in structure to obscurin, 
and are known to resist force 
Figure 1-1:  A train representing the structure of 
obscurin.  The train cars are similar to the domains 
which are linked together in a long chain. 
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through stretch.  The flexibility and behavior of obscurin when stretched is not well 
studied.  Obscurin studies will provide insights into how our cells use the cytoskeleton to 
translate physical force into biochemical signals and resist strain.  Our approach is to 
examine obscurin very closely outside the cellular milieu.  This provides us with a 
simplified model, which we can then extrapolate into the entire cell.  Likewise, since 
obscurin is so large, we cannot study the entire protein but instead small parts of the 
protein that, for a variety of reasons, are likely to be representative of how the rest of the 
molecule works.  In this way, this work is highly reductive.  However, due to the technical 
limits of the techniques that we employ, this simplified version of obscurin must be used.  
In this introductory chapter, I explain why we study obscurin, why we chose to study the 
regions we chose, and how the biochemical techniques we use can provide visual details 
and functional clarity to a world that is far too small for even the most powerful microscope 
to visualize.   
While obscurin is small relative to everyday objects, it is extremely large relative to 
many other proteins.  The size and nature of obscurin creates many difficulties in isolating 
and studying it, due to the fact that traditional protein structure analysis techniques are 
not applicable to the whole obscurin protein.  NMR is only suitable for proteins less than 
30 kDa, X-ray crystallography does not work well with flexible systems, and Cryo-EM 
requires pure soluble protein (which thus far precludes studying obscurin).  Thus, we use 
a reductive approach in studying its flexibility.   
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The architecture of obscurin is similar to a long train (Figure 1-1)3.  Each train car 
represents a single domain, linked together in a long chain.  There are different types of 
domains in obscurin, but the most common is the immuno-globulin like (Ig) domain.  There 
are approximately 60 of these Ig domains in the full protein, and they are mostly 
connected by short linkers (4-5 amino acids between the domains) (Figure 1-2)5.  There 
are two types of short linkers, those that contain proline (an amino acid) and those that 
do not.  Prior knowledge of proline in protein structures suggests short proline linkers 
would be less flexible than short linkers without proline.  We chose four sets of dual 
domain systems:  two with short proline linkers and two short linkers without proline. 
These dual domain systems are representative of ~70% of the obscurin molecule (Figure 
1-2)5. 
Obscurin is known to have both structural and functional roles in cells, and thus it 
appears likely that the protein is somehow involved in force resistance.  Here, we attempt 
to more directly test obscurin’s ability to bend and flex.  We used dual domain systems 
(two domains and the linker connecting them) to explain the behavior of the entire protein.  
Since the domains themselves are functional apart from the rest of obscurin, it is clear 
that the results gathered from these dual domain systems can be extrapolated for the 
whole obscurin protein.  Most of the domains we studied here have previously solved 
Figure 1-2:  The architecture of obscurin, the Ig 
domains are shown in yellow. 
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structures using nuclear magnetic resonance (NMR).  These domains were not entirely 
representative of the global obscurin protein (two sets of domains have proline linkers 
and one set has non-proline linkers.  In order to create a more representative study, the 
NMR structure of another domain (to form another set of domains with a non-proline 
linker) is necessary. 
Nuclear Magnetic Resonance (NMR) 
Our lab specializes in protein NMR structure, function, and analysis studies.  NMR 
is an experimental technique that can be performed on molecules and proteins, which 
can show the chemical environment of each atom or amino acid residue in the protein.  
When atoms are in different chemical environments, they have different NMR signals that 
elucidate structural information.  In order to solve a protein structure using NMR, there 
are a number of experiments that must be performed.  The protein must first be labelled 
using 15N and 13C, isotopes of nitrogen and carbon that can be recognized by the NMR.  
For small molecules, one-dimensional NMR experiments are sufficient.  Two and three 
dimensional NMR experiments are necessary to completely solve the much larger protein 
structure.  These dimensions are analogous to a book.  One-dimensional experiments 
are similar to a word or a line of a page, two-dimensional experiments are similar to an 
entire page of text, and three-dimensional experiments are similar to the thickness of the 
book.  When the protein sample is placed into the NMR, it is subjected to an external 
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magnetic field (Figure 1-3)6.  This magnetic field affects each atom of the sample 
differently depending on where they are located in the structure.  One experiment, 
heteronuclear single quantum coherence (HSQC), is two dimensional and is similar to a 
roadmap for proteins.  Each amino acid in the protein has its own peak on the spectrum.  
This experiment is used in conjunction with the three-dimensional experiments to 
determine which peaks are associated with each amino acid.   
In addition to three dimensional experiments, nuclear Overhauser effects (NOEs) 
are used to determine a protein structure.  NOESYs are experiments that show which 
atoms are near each other in the three-dimensional space of the protein structure.  This 
helps to create an idea of the structure of the protein, because NOEs show which amino 
acids are near each other when the protein is fully folded.  These experiments allow us 
Figure 1-3:  Cartoon model of how nuclei of atoms are affected 
by the external magnetic field of an NMR. 
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to assign each amino acid to certain peaks on the NMR spectra, and create an accurate 
and high resolution structure (meaning we are highly confident in the positions of each 
atom in the structure within a small range) of the protein of interest.  Simulated annealing 
programs are also used in order to determine the structure of the protein.  These computer 
programs use the NMR data and assignments to simulate folding the protein into different 
conformations, giving violations (if the conformations do not match the NMR data) and 
energy values (the average energy value of each atom in the structure calculated from a 
forcefield similar to what is described in the MD section).  A structure is considered ‘good’ 
when the programs give very few violations, and all of the conformations agree with one 
another. 
 NMR chemical shift perturbation maps show differences between protein 
structures.  Differences occurring between the spectra indicate the areas of the proteins 
interact.  When proteins interact, the chemical environment around their interaction site 
is changed, which produces a change in the NMR spectrum.  Peaks on the spectra that 
overlap indicate that the areas of the proteins to not significantly interact with each other.  
Small Angle X-ray Scattering (SAXS) 
SAXS is another experimental technique used to determine the conformation of 
the dual domains in solution.  The protein sample is illuminated by an X-ray beam, the 
beam is scattered off of the protein in solution, and this creates a scattered intensity profile 
(Figure 1-4)7.  When analyzed, the intensity and scattering of the pattern provide 
information  
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 about the conformation/orientation of the protein.  SAXS data is obtained in reciprocal 
space, so a Fourier transform must be performed in order to analyze the data in real 
space.  This transformation along with a Guinier analysis (a mathematical technique to 
analyze SAXS data) provides an Rg value, or a radius of gyration.  Since the protein 
sample is in solution, this protein exists in many conformations.  The Rg value is an 
average of all of the conformations of that sample, as it can freely move in solution.  The 
Rg value is used to find the length of the molecule, and this information helps to elucidate 
the average conformation of molecules in solution. 
Molecular Dynamics/Steered Molecular Dynamics (MD/SMD)  
In addition to the experimental techniques above, we also performed MD and SMD 
simulations on the representative constructs.  These computational techniques allowed 
us to analyze the domains more closely (on an atom by atom basis).  MD is a simulation, 
or computer model.  A protein structure model is placed in an environment full of water 
molecules and the simulation predicts how the protein will behave.  The program treats 
Figure 1-4:  Diagram of how SAXS data is collected.  The scattering curve is used to 
determine the Rg values for the sample. 
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each chemical bond as a classical spring and uses Newton’s laws of motion to predict 
where each atom would be after a small amount of time (2 x 10-15 seconds).  After this 
initial time step, the program recalculates the location of each atom, and this process 
continues until a sufficient amount of time has been reached (generally in the 10-5/10-6 
timescale).  A forcefield accounts for various forces that molecules would experience, 
such as bond stretching, bond bending, bond twisting, and non-bonding terms such as 
electrostatic interactions.  SMD is similar to MD, but instead of the protein model moving 
randomly, SMD samples low-probability states that would be unlikely to occur in MD.  In 
this case, we simulated what would happen to the dual domains if they were pulled apart 
at a constant rate (0.1 m/s).  This pulling adds another spring to the system, attached to 
both ends of the dual domains.  While unlikely to occur in MD, this SMD simulation 
represents the type of movement and stretch that obscurin would be subjected to in 
Figure 1-5:  Diagram of a muscle cell.  Obscurin is shown in blue, connecting 
the sarcoplasmic reticulum to the contractile apparatus of the muscle.  The 
sarcoplasmic reticulum can move, and obscurin tethers it. 
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muscle cells (Figure 1-5)8.  It is easy to imagine how obscurin (blue) would stretch if the 
gray areas began to pull apart from each other.   
Chapter 1 is a brief overview and explanation of the techniques described in 
chapter 2.  The next chapter will explain the experimental results in more detail. 
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Chapter 2 
Introduction 
            Most cells in the body are subjected to motion, ranging from muscle cells 
contracting and relaxing to epithelial cells conforming to body movement.9  Yet cells also 
must be physically strong to maintain homeostasis and normal architecture amidst this 
strain.10  Giant cytoskeletal proteins are long, chain-like molecules that connect distal 
cellular regions and have the capacity to bend and stretch.5,11–13  Thus, these proteins 
provide a potential mechanism to assist the cell in its capability to be both flexible and 
strong.  
            The most well known giant cytoskeletal protein is titin.  This protein spans from 
the Z-disk to the M-band in myocytes, and is mostly comprised of hundreds of 
consecutive, individually-folded Ig domains.5  Through a domain unraveling mechanism, 
titin acts as a molecular spring, resisting stretch force longitudinally as the muscle cell 
overextends.14–17 
Obscurin, another giant cytoskeletal protein, has a similar architecture to 
titin.5,8  This protein can be found in at least 20 different forms, ranging from 20 kDa to 
970 kDa.1  At its longest, the N-terminal two-thirds of the protein is comprised of over 60 
tandem Ig and Fibronectin (FnIII)-like domains connected to their neighbors via short 
linkers.18  The C-terminus contains multiple signaling domains (i.e. PH, RhoGEF, IQ)18,19 
and either an ankyrin binding region (in obscurin A isoforms)20 or kinase domains (in 
obscurin B isoforms).21  Obscurin’s multiple functions are closely linked to its complex 
subcellular localization.22,23 In skeletal muscles, the ankyrin binding region of obscurin A 
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binds to small ankyrin 1 (sAnk1) at the sarcoplasmic reticulum.20,24–26  Ablation of this 
interaction reduces sAnk1 levels, which in turn leads to aberrant Ca2+ homeostasis.27–29 
Likewise, obscurin interacts with ankyrin-B in the costamere.  When this interaction is 
disrupted, skeletal muscles experience increased exercise-induced damage due to the 
improper assembly of the dystrophin complex.30  Obscurin B binds to and phosphorylates 
N-cadherin at the intercalated disk in cardiomyocytes, suggesting that it may modulate 
muscle cell adhesion.21  Complementing these membrane-associated interactions, 
obscurin binds to the sarcomeric contractile apparatus in several locations.5  The 58th-
59th obscurin Ig-like domains form a complex with the titin ZIg9 domain at the Z-disk 
during development, suggesting obscurin plays a role in myofibrillogenesis.18,28,31–33  
Additionally, the N-terminus of obscurin interacts with titin, slow myosin binding protein 
C, and myomesin at the M-band, contributing to the M-band lattice assembly, structure, 
and strength.34–37  Thus, obscurin forms the only known connection between the muscle 
contractile apparatus and the surrounding membrane structures.5,34,38,39  Clinically, 
obscurin is linked to breast and colorectal cancers, and obscurin knockdown cells 
undergo epithelial-to-mesenchymal transition.40–42  In muscle, specific obscurin mutations 
that alter target protein binding are causally linked to hypertrophic cardiomyopathy, 
dilated and restricted cardiomyopathy, and muscular dystrophy.38,43–47  
In order to better understand both how obscurin exists in solution and responds to 
stretch, here we study a series of representative tandem obscurin Ig domains using 
structural biology and computation techniques.  We find these dual domain constructs are 
predominantly extended in solution, yet the domains are also moderately mobile relative 
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to each other.  This finding led to the question of how these domains could be extended 
(suggesting a framework to maintain this conformation) and also flexible (suggesting that 
there is not a significant framework present).  MD simulations suggest that transient 
noncovalent bonds between mobile regions in neighboring domains are largely 
responsible for these dual domains being extended yet dynamic. 
 
Results 
Implicit in the observation that obscurin links various cellular targets to each other 
is the fact that the protein must act as a tether.  While obscurin-target interactions in 
muscle are increasingly well documented, the conformation and dynamics of the obscurin 
region between these anchor points (the tether) are less understood. 5,21,27,34,35,43  Here, 
we investigate obscurin’s conformation in solution.  In an effort to more easily collect high-
resolution information about this protein, we utilized a reductive approach and studied a 
series of representative obscurin dual-domain systems.  The linkers between obscurin 
domains can be broadly divided into short linkers containing proline residues (48% of all 
obscurin linkers), short linkers with no proline residues (22%), and long linkers (>6 
residues) (30%) (Table 2-1).  Previous studies, plus basic biochemistry knowledge, 
suggest the proline-containing linkers may be more rigid, and long linkers are almost 
certainly more flexible.48  Here we study two constructs with proline-containing linkers and 
two constructs with proline-absent linkers to better understand the mobility these short 
linkers confer on the obscurin molecule as a whole.   
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Table 2-1:   
The linker between each human obscurin Ig domain 
Numbered Ig domains from obscurin (CAC44768.1) 
 Linkers- We define the linker as the residue following the last lysine (or arginine) in 
one domain to the residue preceding the first lysine (or arginine) in the next domain.  These 
were all aligned to the Ig34-39 region, and include the final and first residues of the flanking 
domains.   
 Note that in this nomenclature, Ig57, Ig58, and Ig59 are numbered 47, 48, and 49. 
 
Type of Linker Linked 
Domains 
Linker Sequence 
Long 1-2 daeaacaeqaph 
Long 2-3 dsdaadtasrpgtstaallahlqrrreamraegapasp 
Short proline containing 3-4 repavp 
Short non-proline 
containing 
4-5 qgnl 
Long 5-6 saprkppl 
Long 6-7 vhlapkla 
Long 7-8 raapgltankp 
Long 8-9 qglarflh 
Long 9-10 sepkvvfak 
Long 10-11 kepkvvfak 
Long 11-12 tepkmmfak 
Long 12-13 tepkgvfak 
Long 13-14 tepkavfak 
Long 14-15 sepkavfak 
Long 15-16 aepkvvfak 
Long 16-17 aepkavfak 
Long 17-18 aepkvvfak 
Short proline containing 18-19 epqise 
Short non-proline 
containing 
19-20 aak 
Short non-proline 
containing 
20-21 srvvk 
Short proline containing 21-22 eapvl 
Short non-proline 
containing 
22-23 emrqvr 
Short proline containing 23-24 telpvs 
Short proline containing 24-25 kelpvt 
Short non-proline 
containing 
25-26 eeqsit 
Short proline containing 26-27 sdipvv 
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Short non-proline 
containing 
27-28 earevt 
Short proline containing 28-29 rvkpvv 
Short non-proline 
containing 
29-30 hdlhvg 
Short proline containing 30-31 rerpaa 
Short non-proline 
containing 
31-32 anc 
Short non-proline 
containing 
32-33  qgrrvh 
Short proline containing 33-34 tekpsv 
Short proline containing 34-35 harpvr 
Short proline containing 35-36 talpaq 
Short proline containing 36-37 rpmpah 
Short proline containing 37-38 kalpak 
Short proline containing 38-39 ralpar 
Short proline containing 39-40 ralpik 
Short proline containing 40-41 rampsk 
Short proline containing 41-42 ralpar 
Short proline containing 42-43 rapqpv 
Short proline containing 43-44 taapvr 
Short proline containing 44-45 rvprpk 
Short proline containing 45-46 tepevt 
Short proline containing 46-47 rapevt 
Short non-proline 
containing 
47-48 taknt 
Short non-proline 
containing 
48-49 rgwrle 
Short proline containing 49-50 lglpd 
Short proline containing 50-51 ppkpv 
 
Multiple solution structures of individual obscurin Ig-like domains are already in the 
Protein Data Base (PDB; Table 2-2).  Included in this set of structures are many that 
connect to neighboring domains via short proline-containing linkers (i.e. Ig34, Ig35, and 
Ig36 in full-length obscurin).18  However, only two published structures- Ig58 and Ig59- 
are connected with a non-proline linker.43,44  Therefore, in order to generate a more robust 
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data set for studying domain/domain motion, we first solved the solution structure of Ig57, 
a domain that connects to Ig58 via a non-proline linker.  The heteronuclear single  
Table 2-2: 
PDB accession numbers of solution structure human obscurin Ig-like domains (from CAC44768) 
 
 PDB code Obscurin domain Position  
 2ENY  Ig27   2735-2825 
 2EDF  Ig28   2826-2915 
 2EDR  Ig34   3361-3449 
 2EDT  Ig35   3449-3537 
 2EDW  Ig36   3537-3630 
 2EDH  Ig37   3614-3713 
 2EDQ  Ig38   3713-3806 
 2EDL  Ig39   3801-3897 
 2MWC  Ig58   4342-4430 
 2N56  Ig59   4430-4519 
 
quantum coherence (HSQC) spectrum of Ig57 is well-dispersed, and every backbone 
peak was subsequently sequence-specifically assigned (Figure 2-1A).  The resulting 
solution structure is of high quality, with more than 10 distance restraints per residue and 
no violations greater than 0.40 Å (Table 2-3, Figure 2-2).  The 20 best structures overlay 
well with each other, with a backbone root-mean-square deviation (RMSD) of residues in 
the Ig-like fold being 0.681 ± 0.061 Å.  The best structure, judged by having the lowest 
RMSD, shows Ig57 arranged into a typical Ig-like fold, with its two beta sheets arranged 
into a beta sandwich-like fold (Figure 2-1B). 
Next, we constructed a series of dual Ig domains.  Ig34/35 and Ig35/36 have short proline-
containing linkers, and Ig57/58 and Ig58/59 have short proline-absent linkers (Figure 2-
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3A).  All of the domains, individually, are fully assigned using multidimensional 
heteronuclear Nuclear Magnetic Resonance Spectroscopy (NMR).  For each dual domain 
system, the resulting HSQC is almost exactly the sum of the individual domain HSQCs 
overlaid on top of each other (Figure 2-3B).  This indicates the individual domains do not 
significantly interact with their neighbor, except at the extreme poles where the linker 
connects the two domains (Figure 2-3C).  In addition, there was no evidence of peak 
splitting in any of the HSQC spectra, indicating these tandem domains are either in a 
single conformation, or else are in fast exchange between several different 
conformations.  In all cases, the linker residues between two domains were exchange-
Figure 2-1: Solution structure of Ig57 (residue 4252-4336 of human obscurin).  
A) Fully assigned HSQC of Ig57.  B) Cartoon of the best Ig 57 structure.  Further 
structural analysis can be found in Figure S1 and Table 3. 
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broadened out and could not be assigned, regardless of temperature (37 oC, 25 oC, and 
10 oC).  Additionally, no nuclear Overhauser effect (NOE) correlations were observed  
Table 2-3: NMR-derived restraints and statistics of 20 NMR structures of wild-type Ig571 
        <20>        Best Structure 
Rmsd from distance constraints (Å)	2 
 Total (884)          0.021 ± 0.001   0.018 
 Intraresidue (250)        0.005 ± 0.003   0.005 
 Sequential ( |i - j| = 1 ) (250)      0.013 ± 0.004  0.018 
 Medium range ( 1 < |i - j| < 4 ) (71)      0.031 ± 0.006  0.024 
 Long range( |i - j| > 4 ) (241)      0.022 ± 0.004  0.014 
 Hydrogen bonds (72)        0.042 ± 0.007  0.039 
Rmsd from exptl dihedral constraints (°) 
 F,Y (112)          0.525 ± 0.140  0.538 
Rmsd from exptl 13C chemical shifts 
 13Ca (ppm)          1.350 ± 0.04   1.320 
 13Cb (ppm)          1.740 ± 0.04   1.700 
Rmsd from idealized geometry 
 Bonds (Å)          0.004 ± 0.000  0.004 
 Angles (°)          0.565 ± 0.017  0.545 
 Impropers (°)          0.382 ± 0.021  0.342 
Lennard-Jones potential energy (kcal/mol)	3      -315 ± 8   -333 
% most favorable region in the Ramachandran plot 4  77.6 ± 3.3   72.0 
Rmsd of the mean structure (Å)	5 
 All backbone atoms         0.68 ± 0.06   0.55 
 All heavy atoms        1.26 ± 0.07   1.11 
 
1 The 20 ensemble structures, <20>, are the results of simulated annealing calculations. The 
best structure is the closest to the average structure. The values shown for the <2> are the 
mean ± standard deviation. 
2 None of the 20 structures has a distance violation > 0.35 Å or a dihedral angle violation of > 5°. 
The force constants used in the SA calculations are as follows: 1000 kcal mol −1 Å2 for bond 
length, 500 kcal mol−1 rad−2 for angles and improper torsions, 4 kcal mol−1 Å−4 for the quartic 
van der Waals (vdw) repulsion term (hard-sphere effective vdw set to 0.8 times their values in 
CHARMm parameters), 50 kcal mole−1 Å−2 for experimental distance constraints, 1 kcal 
mol−1 Å−2 for distance symmetry constraints, 0.5 kcal mol−1 ppm−2 for the 13C chemical shift 
constraints, and 1.0 for the conformational database potential. The force constants (in kcal 
Hz−2) used for dipolar coupling restraints is 0.50. 
3 Lennard-Jones van der Waals energies were calculated using CHARMm parameters and were 
not used in any stage of the structure determination 
4 PROCHECK was utilized to generate the Ramachandran plot 
5 Backbone calculations include Cα, N, and C′ atoms. Only residues 3–91 are included since no 
long-range NOE correlations were observed for residues 1–2 and 92–104 (the expression tag). 
 25 
	
between tandem domains or between domains and their adjoining linkers, supporting the 
notion that these domains are dynamic relative to each other, and that all short linkers, 
regardless of composition, experience significant intermediate-timescale (µs-ms) 
motions. 
Due to the paucity of inter-domain NOE correlations, we cannot use traditional 
NMR methods to determine the conformation of these dual domains in solution.  
Therefore, we attempted two orthogonal techniques to better understand the solution 
Figure 2-2:  NMR examples of Ig57 experiments.  A) NOESY/TOCSY overlay 
of A87 in Ig57.  B) Backbone walking experiments used to assign Ig57.  C) 
Secondary structure diagram of Ig57 with visible NOE correlations. 
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structures of these tandem domain systems:  small angle X-ray scattering (SAXS) and 
residual dipolar couplings (RDC).  Guinier plots of SAXS data (Figure 2-4A, Figures 2-5, 
2-6) show all dual domain systems are extended in solution and have similar Rg values 
regardless of linker composition (Figure 2-4B).  We next fit our SAXS data to an ensemble 
of tandem domain models, each with different domain/domain angles (Figure 2-4C).  In 
all constructs, the models that best fit the experimental data were almost fully extended, 
Figure 2-3: NMR dual domain construct analysis.  A) Each dual domain construct 
labeled with the linker sequence and PDB ID.  B) HSQC overlay of Ig58 (red), Ig59 
(gold), and Ig58/59 (blue). C) Chemical shift perturbation maps of each dual domain 
system of obscurin.  Residues colored red indicates a significant HN-N chemical shift 
change (>2x st. dev) in the dual domain systems compared to the single domains.  
Note that the chemical shift changes are randomly distributed around the models, 
which suggests that the domains do not significantly interact with each other. 
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in agreement with our Guinier analysis.  However, the residuals of our best fits were non-
random in most cases.  Therefore, we re-fit the data using a two-state model:  one 
extended conformation and the other compact (Figure 2-4D and Figure 2-7).  These two-
state models showed a better fit with the data, suggesting that all constructs are usually, 
but not exclusively, extended.  Further fitting of more complex models yielded       
Figure 2-4:  SAXS analysis of a representative obscurin dual domain construct.  A) 
Guinier plots of two concentrations of Ig34/35: 1 mg/mL (black) and 3 mg/mL (red).  
B) Dimensions of each dual domain system, calculated from the Rg values (Rg = 
√(3*Guinier Slope and Dimension = Rg*2) C) The Ig34/35 best fit model (orange) 
compared to other models (gray), calculated via MultiFoXS.61  D) Comparison of one 
state model fit (orange) and the two state model fit (blue), to Ig 34/35 1 mg/mL 
experimental SAXS data (circles). 
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Figure 2-5:  Guinier and RDC analysis.  A) Zoom in of Guinier regions of Ig34/35 with 
labeled Rg at two concentrations: 1 mg/ml (black) and 3 mg/mL (red).  B) RDC 
experimental data on Ig58/59.  C) Using PALES, The fit of each individual domain and 
the dual domain of Ig58/59 to experimental RDC data. 
Figure 2-6:  Guinier plot and Guinier region zoom in for each dual domain system at 
two concentrations.  A Ig35/36 at 1 mg/mL (black) and 3 mg/mL (red).  B) Ig57/58 at 
1.2 mg/mL (black) and 1.4 mg/mL (red). C) Ig58/59 at 2.5 mg/mL (black) and 3.0 
mg/mL (red). 
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progressively better fits.  As additional evidence of this apparent flexibility, RDC data on 
two of the tandem constructs (Ig35/36 and Ig58/59) show while the individual domains fit 
the data well, the data cannot be forced to fit any single dual domain model (Figure 2-
5A/B).  In sum, for every dual construct we tested, we conclude tandem Ig domains are 
relatively extended but can also exist in multiple conformations.   
The finding that every tandem dual domain system is both extended yet flexible 
seems paradoxical.  To address the problem of how these systems can simultaneously 
have this kind of structure and flexibility, we require high-resolution information of the 
various domain/domain interfaces.  However, no NOE measurements exist between any 
of these regions.  Additionally, this apparent domain/domain flexibility precludes x-ray 
crystallography analysis due to the potential of significant crystal packing artifacts.  
Therefore, we turned to molecular dynamic simulations (MD) in an attempt to find possible 
domain/domain or domain/linker interactions.  All subsequent tandem domain models 
were first equilibrated for >50 ns, and the angle between the domains in solution was then 
measured over an additional 50 nanoseconds in triplicate (Figure 2-8A).  In all 
simulations, each of the dual domain systems maintained a relatively extended structure 
on average, but the inter-domain angle varied widely, with a maximum change of 
orientation ~50-70 degrees.  A global examination of these simulations suggests these 
extended conformations are the result of steric hindrance between the domains; 
neighboring domains with short linkers clash into each other if the angle between them is 
Figure 2-7:  (Previous page) Comparison of MultiFoXS one state and two state fits to 
experimental SAXS data of each dual domain system at two concentrations.  A) 
Ig34/35 at 3 mg/mL.  B) Ig35/36 at 3 mg/mL.  C) Ig35/36 at 5 mg/mL.  D) Ig57/58 at 
1.2 mg/mL.  E) Ig57/58 at 1.4 mg/mL.  F) Ig58/59 at 2.5 mg/mL.  G Ig58/59 at 3 mg/mL.   
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less than ~120 degrees.  These elongated but dynamic dual domain systems persist at 
least into the microsecond regime (Figure 2-9), and are in excellent agreement with our 
experimental data.  
Closer examination of these MD trials showed that in all simulations, multiple 
residues at the domain poles participate in long-lived, stabilizing interactions with moieties 
in the linkers (Figure 2-8B).  Once these interactions form, they usually persist for the 
duration of the simulation and are largely independent of domain/domain bending.  To 
study these interactions in more depth, we next performed steered molecular dynamics 
Figure 2-8: Molecular dynamics analysis of dual domain constructs.  A) Domain angle 
vs time graph.  B) Snapshot of the Ig34/35 domain/domain interface, showing likely 
interactions between the domains and the linker. 
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simulations (SMD) on these systems, where the domain termini were moved apart at a 
constant velocity of 1 Å/ns.  By elongating the dual-domain systems, SMD gives a more 
controlled setting to study how these putative inter-domain and domain/linker interactions 
respond to bend and stretch.  SMD also simulates a physiologically reasonable timescale 
of stretch,4,49 and thus gives us insight into how obscurin may respond to stretch in the 
cell.  
When a slightly bent dual domain system is stretched, the domains first straighten, 
yet many of the inter-domain and domain/linker interactions remain intact (Figure 2-
10A/B).  This is accompanied by the addition of either no or very little work to the system 
(Figure 2-10C).  Only after the domains completely straighten does the linker begin to 
extend and these interactions begin to break (Figure 2-10D).  Thus, these noncovalent 
interactions, originating on linker regions or on loops within the Ig domains, are both long-
lived and flexible.  The existence of such flexible interactions explains how dual domain 
Figure 2-9: Angle between the domains of Ig58/59 calculated from MD over a period 
of ~800 ns. 
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systems can simultaneously be extended and dynamic.  Despite each construct having a 
different composition, all four sets of dual domain systems displayed this same behavior 
(Figure 2-11).  As the domains are stretched further, increasingly more work must be 
added to the system until individual domains unravel.  This kind of work-stretch profile 
occurs in all model constructs, and is reminiscent of other well-studied multi-Ig-domain 
systems.16,50  These domain-rupturing events present an oft-used cellular mechanism 
through which obscurin can resist large stretch forces.17 
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Figure 2-10: Representative steered molecular dynamics analysis.  A) Domain angle 
vs time graph of Ig34/35.  B) Distance between the functional groups in one Ig34/35 
simulation.  In these measurements, distances of ~5-6 Å denote the distance of a 
hydrogen bond in this trace. C) Work vs. time graph of Ig34/35.  D) Hierarchical 
model of obscurin extending with increasing stretch.  Domains first straighten, 
followed by linker straightening, followed by domain unraveling. 
 35 
 
 36 
 
 37 
Discussion 
The N-terminal majority of obscurin is composed of unique Ig-like and FnIII-like 
modular domains.  Of the approximately 60 linkers that connect these domains, around 
70% are 3-4 residues in length.  Here, we study four representative short linkers.  Dual-
domain systems with proline-containing linkers and dual-domain systems with proline-
absent linkers are equivalently flexible in solution.  Domain/domain orientation tends to 
be around 160 ± 20o: almost fully extended.  MD studies suggest these multiple 
orientations are of near-equivalent energies, and thus experimental high-resolution 
techniques are inadequate for studying this type of multi-domain dynamic system.  
Through extensive MD simulations and analyses we find, in all constructs, short linkers 
facilitate specific domain/linker and domain/domain interactions.  These interactions 
occur predominantly on loops and other disordered regions of the protein, and can 
tolerate both moderate compression and stretch.  While the exact bonds that form are 
inherently unique at every interface, each construct we have studied exhibits multiple 
examples of these interactions.  The overarching conclusion is while short linkers facilitate 
such interactions, the regions containing these bonds are sufficiently flexible to allow 
significant domain motion.  However there is a limit to this flexibility; when the domains 
bend excessively, the surfaces begin to bump into each other thus resisting further 
bending.  Thus the existence of short linkers may be a mechanism in multi-domain 
Figure 2-11: (Previous page) SMD simulations for each dual domain system.  A) 
Domain angle vs time graph of Ig34/35 (top), work vs time graph of Ig 34/35 (middle), 
and distance between residues of likely interactions vs time of Ig 34/35 (bottom) for 
three different SMD simulations.  B) SMD data on Ig35/36, following the same 
organization as (A).  C) SMD data for Ig57/58.  D) SMD data for Ig58/59. 
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proteins to avoid unwanted domain/domain clamshell formation.  Conversely, when two 
extended domains are pulled apart, interdomain bonds break well before the domains 
themselves rupture.  
Previous structural studies of a similar system in titin concluded that short linkers, 
similar to those present in obscurin, lead to an extended conformation of Ig domains, and 
this conformation is maintained through a series of domain/domain and domain/linker 
non-covalent interactions.48  However, computational studies on these same systems 
suggest that consecutive domains are flexible relative to each other.14  Thus, the idea 
presented in this study, that short linkers in obscurin facilitate domain/domain and 
domain/linker interactions and these interactions can tolerate domain motion, reconciles 
longstanding discrepancies between experimental and computational work on the 
molecular flexibility of titin.14,48  
 From the data gathered here, we created a simple model of how obscurin behaves 
in solution (Figure 2-12).  In this model, we assumed the obscurin molecule is unhindered 
between the beginning and the end of its tandem Ig region (i.e. it participates in no target 
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binding in the middle of the molecule), the Ig region consists of 60 domains, each domain 
is 4 nm in length, and a two-domain system bends a maximum of 45 degrees away from 
180 degrees.  With these inputs, one can create a random walk trajectory (for example, 
see Figure 2-12A).  Figure 2-12B shows a distribution curve of the distance between the 
termini of this model and suggests they will be, on average, around 76 nm apart from 
each other in solution.  Of note, the input values can be altered, resulting in minor changes 
in the average termini distance (Figure 2-13).  In this model, it is worth noting that the 
distance between termini range from 0 nm to ~239 nm.  Given these constraints, and 
given the work that others have done on similar proteins, a reasonable model of this 
system is a worm-like chain model.48,51  Thus, with knowledge of the persistence length 
and contour length, we can calculate the entropic energy required to completely extend 
obscurin (to 239 nm), and we find this force is small: only around 28 J/mol.  Further  
Figure 2-12:  Simplified model of obscurin dynamics in solution.  A) Five examples of 
random-walk simulations, where the i+1 domain is allowed to bend between 0 and 45 
degrees in any direction relative to the i domain.  This model is of 60 domains.  B) The 
end-to-end distance distribution curve of 100,000 simulations, showing that the 
obscurin N and C termini are most often roughly 76 nm apart from each other, given 
the inputs specified. 
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flexible noncovalent bonds to break in order to fully extend each linker   From our SMD 
Figure 2-13: Modeled average length of obscurin. A) The average obscurin length as 
a function of domain angle (in degrees). The number of links = (number of domains -
1) for each model. B) The average obscurin length as a function of link number. The 
plots represent what angle the linkers can bend. These models were generated in the 
XYZ dimensions. 
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separation of the termini, up to around 270 nm (or around 5 Å per linker), requires the 
flexible noncovalent bonds to break in order to fully extend each linker region.  From our 
SMD measurements, this extension is associated with 1-10 kJ/mol of work per linker.  
This extension range is likely where obscurin behaves as a physiologically relevant 
molecular spring.51  Extension past 270 nm begins unraveling individual Ig-like domains, 
and requires a significant amount of work, likely in a manner reminiscent of how titin 
resists overextension.17  Thus, if obscurin links two distal targets at each termini, it will 
behave as a slack rope as long as those targets are less than 240 nm from each other.  
As the targets separate further, obscurin begins behaving as a spring, progressively 
resisting more force as the objects are moved farther apart from each other.  This model 
presents obvious control points to tune such a system; adding additional anchor points to 
obscurin through interactions with domains in the middle of the protein, will 
correspondingly reduce the chain length and create a stiffer spring.  Our model is overly 
simplistic; obscurin contains several regions of longer linkers (Table 2-1), and some 
tandem domains may more strongly interact with each other.  Additionally, parts of the 
obscurin C-terminus are non-modular and other parts contain signaling domains, which 
our model does not take into account.  Further research in these other obscurin regions 
will lead to a more refined model, and should provide more detailed insights into how 
obscurin behaves in the context of the myocyte. 
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Conclusions 
Here we show obscurin tandem Ig-domains adopt an elongated orientation in 
solution.  Despite staying moderately extended, the domains have a range of flexibility.  
This physical characteristic is brought about through the soft interface between 
neighboring Ig domains, and the interactions this interface creates.  These interactions 
are postulated to help prevent self-association with neighboring domains.  As a 
consequence of this elongated-yet-dynamic structure, obscurin does not significantly 
resist stretching force until the inter-domain linkers, and eventually the Ig domains 
themselves, begin to unravel.  This hierarchical stretching profile allows for a simple 
model of obscurin flexibility. 
 
Materials and Methods 
 
Protein Isolation 
All chemicals were ACS grade or higher and were purchased from Fisher 
Scientific, unless otherwise specified.  Recombinant 15N, 15N-13C, and unlabeled protein 
were purified after overexpression in Escherichia coli (BL21(DE3)) using pET24a vector 
system (Novagen, San Diego).  All constructs were induced at 37°C with 100 µM IPTG at 
an OD600 = 0.6 and grown for additional 4 hours at 37°C.  Cells were sonicated and 
centrifuged in a small amount of buffer containing 50 mM phosphate pH 8.0, 
300 mM NaCl, 10 mM imidazole and 1 mM PMSF.  The resulting cleared supernatant 
was passed over Ni-NTA His-bind Resin (Novagen).  The column was washed 
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extensively with 50 mM phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole buffer, and 
eluted with the same buffer plus 500 mM imidazole.  Fractions containing the protein were 
then concentrated in 5000Da MWCO concentrators (Corning SpinX, Tewksburg, MA) and 
applied to a Sephadex G75 (Sigma; St. Louis, MO) size exclusion chromatography 
column in 50 mM Tris pH 7.5, 20 mM NaCl, 0.35 mM NaN3 (G75 buffer).  Pure protein, 
as determined by SDS-PAGE, was once again concentrated in a 5000Da MWCO 
concentrator.  
  
NMR 
All data for NMR experiments were collected on a 600 MHz Bruker Avance II 
spectrometer equipped with a TXI room temperature 5 mm probe with z axis pulse field 
gradient coils. NMR samples were either collected at 10°C (for Ig 57) or 10-37°C (for all 
other samples) in 20 mM Tris pH 7.5, 20 mM NaCl, 0.35 mM NaN3, and 0.3-1.0 mM 
protein with 10% D2O.  For Ig57, we collected a 2D HSQC and standard 15N-edited triple 
resonance experiments including HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, 
C(CO)NH, HCCCONH, 15N-edited TOCSY, 15N-edited NOESY and 13C-edited NOESY, 
in as previously described.44,52  For other constructs, we collected 3D HNCACB, 
CBCA(CO)NH, HNCO, HN(CA)CO data along with 2D HSQCs.  Most experiments were 
collected with 128, 64, and 1024 points in the T1, T2, and T3 dimensions, 
respectively.  NMR data were processed with NMRPipe,53 extended in the indirect 
dimension via linear prediction, and the resulting spectra were analyzed via Sparky.54  In 
all samples, all visible HSQC backbone shifts were assigned.  Chemical shifts for the 
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obscurin Ig57 domain have been deposited in BMRB under the accession number 
30514.  Ig34, Ig35, and Ig36 chemical shift assignments were kindly provided by Dr. 
Ayako Nomura (Riken Structural Biology Laboratory, Japan). 
 
 
Structure Calculation 
Interproton distance constraints were derived from 3D NOESY experiments (15N-
edited and 13C-edited 3D NOESY) as described previously.43  Dihedral constraints y ± 
20˚ and f ± 15˚ for a-helix and y ± 40˚ and f ± 40˚ for b-sheet were included based on 
TALOS+ and the chemical shift index of 1Ha and 13Ca atoms.55,56 Structural calculations 
were performed as described in References 23-24. Out of 200 structures, the final 20 
were selected based on lowest Q-values and lowest RMSD from the average, and were 
of high quality based on the statistical criteria listed in Table 2-3.  The overall backbone 
RMSD of ordered heavy atoms is 0.609Å.  The coordinates of the human obscurin Ig57 
structure have been deposited in the Protein Data Bank 6MG9. 
 
Residual Dipolar Coupling (RDC)  
Anisotropic IPAP experiments for RDC determination were performed using the 
same conditions as for the HSQC with the exception of using a stretched polyacrylamide 
gel.52,57  The gel was prepared using 4% acrylamide, and soaked with buffer prior to 
soaking with protein.  RDC values were calculated using PALES software. 58 
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Small Angle X-ray Scattering (SAXS) 
Different concentrations (1.0, 3.0, and 5.0 mg/mL) of various obscurin samples 
were prepared in the NMR buffer. SAXS data were collected at the 12-id-B beamlines of 
the Advanced Photon Source (Lemont, IL) as previously described.59  Guinier plots were 
created using Origin, and the radii of gyration of the protein constructs were calculated 
with the Guinier approximation.60  MultiFoXS was used to analyze the fit of SAXS and 
RDC data together, as well as to back-calculate the conformation that best fit the SAXS 
data.61  
  
Molecular Dynamics (MD) 
All MD simulations were performed using the YASARA 12.4.1 software package, 
the Amber 03 force field, and explicit solvent (with 150 mM NaCl) in a box that extended 
5 Å beyond the length of the extended construct at 37°C, and described in reference 43. 
All simulations were run for at least 50 ns in triplicate. 
            All steered molecular dynamics simulations were performed using the PMEMD 
module of the Amber 14 MD software package, using AMBERff12SB force field and in 
explicit solvent.4,62–64  For equilibrium simulations, a constant temperature of 300K was 
imposed using a Langevin thermostat with a collision frequency of 1 ps-1. A constant 
velocity of 1.0 Å/ns (0.1 m/s) was used in order to simulate biologically relevant pulling 
forces.65  The SMD spring constant (rk2) was set to 0.2 and the temperature used was 
310.0 K.  Analysis was visualized using Gnuplot.62  
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Obscurin Modeling 
 A mathematical model for obscurin was created using a 4 nm rod for each domain 
and nine degrees of freedom between each domain (135, 180, 225 degrees in the x, y, 
and z direction, along with diagonals).  Rods are connected at random in one of the nine 
degrees of freedom.  The total distance calculated is measure from the first rod to the 
final rod.  The model was implemented using MATLAB.66  The WLC formula 
𝐹 ≈ 𝑘$𝑇𝐿' ( 14(1 − 𝑟/𝐿/	)2 − 14 + 𝑟𝐿/4 
was used, where kB is the Boltzman constant, T is temperature in Kelvin, LP is the 
persistence length calculated in MATLAB, r is the distance between the N and C termini 
of our model, and Lc is the fully extended chain (the contour length).67 
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Appendix 
 
SAXS Analysis Tutorial and Instructions 
 
SAXS Analysis Instructions- through Guinier analysis. 
NOTE:  this requires the use of Origin, which is not a free program!!  However, most schools 
have educational copies floating around.  But just FYI:  If you are doing this at home, you’ll 
need to first pay for this program. 
 
Use Origin to analyze all files 
This set of instructions is to analyze SAXS data. This guide will be not showing how to collect 
SAXS data, and begins with already collected data that has been mildly organized. Additionally, 
this guide is written for elongated systems, but the same analysis techniques apply. If the 
protein of interest is globular, only one Rg value needs to be calculated. 
The files of interest should be called something like filename_all.dat and filename_av.dat 
_all.dat files are all of the data for that sample 
_av.dat files are the average of the data for that sample 
Naming convention Example:  for the data from the 1.1 mg/ml concentration of Ig3637, which 
was the 93rd sample ran, we named it 3637c1p1_00093.  The _all.dat file should be 
3637c1p1_00093_all.dat.  The _av.dat file should be 3637c1p1_av.dat.  The c stands for 
concentration and the p stands for “point”.  Origin doesn’t work well with special characters 
like periods. 
 
1.  the _all.dat files need to be looked at individually to make sure that there are no outliers. 
 Importing Multiple Files:  Open Origin – Under the word “Image” in the tool bar, click 
the icon that looks like 123 with an arrow to two speadsheets (shown below).  This is called 
import multiple ASCII.  (We will use this button to import every file in the future).  Then 
navigate to where the data files are saved and open the _all.dat of 1 concentration of the 
sample you want to look at.  To sort only by _all.dat files and have no _av.dat files show up, 
type *all* into the file name box.  There should be around 3 concentrations per sample.  Click 
on the file, click add file, and then Ok.  A Dialogue Box should open, but nothing needs to be 
changed so click Ok. 
 
The file should load into Origin.  Column A is the Q value and all other columns are the actual 
data.  Highlight all columns except for column A by clicking on B and dragging to the end of the 
sheet.  Once highlighted, there is a button in the bottom left of the window that looks like a 
diagonal line (shown below).  Click it and a graph should open. 
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The graph should look like an L or a right angle (shown below), and the scale of the axes needs 
to be changed.  Double click on the x axis and change the “type” from Linear to “Log10” and 
change “From” from 1E-11 to 1E-3 or so. Click Apply.  In the same dialogue box on the left, click 
on “Vertical” to edit the Y axis.  Change the “type” to “Log10” again and change “from” to 
about 1E-2.  Click OK.  In the area of about .01 to .1 on the X axis, look to see that all of the lines 
more or less take the same path (shown below).  If there are any outliers that are drastically 
different from the rest, find which column it is and delete it.  If nothing needs to be deleted, the 
_av.dat files are good to use.  If something was deleted, a new _av.dat file needs to be made for 
that sample.   
 
 
Do this for all concentrations of each sample. Then close the origin window. 
2.  All of the _av.dat files for the sample need to be loaded into Origin. Only add the av files of 
the same sample, but different concentrations. 
 Using the same method as above in a new window, add in every concentration to 
Origin.  Find a file, click add file, find the next concentration, add file, etc. until all 
concentrations for that sample have been added.  Next add the Buffer_av.dat file.  To sort only 
by _av.dat files and have no _all.dat files show up, type *av* into the file name box.  Use the 
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Buffer file that is the closest to the number on the sample files. It is ok to import more than one 
buffer. 
 Example – if you have 3637c1p1_00093_av.dat.  and you have 3 Buffer runs named 
Buffer1_00085_av.dat, Buffer2_00090_av.dat, and Buffer3_00099_av.dat, load in Buffer2 
because that is the buffer that was run closest to that sample. 
When all files have been added, click OK.  The dialogue box should open, and under “Import 
Options” -> “Import Mode”, change it from “Replace Existing Data” to “Start New Columns.” 
Now all of the concentrations and buffers are loaded into one window.  They are not labelled, 
but they are in the order that they were added, so make sure to write that down.  Each file has 
3 columns, so the first 3 columns are the first file you added, next 3 columns are the second file 
etc.  The first column of each file is the same so you only need one of them. We will keep 
column A.  The second column of each file is the actual data we want.  The third column of each 
file is the standard deviation.  These third columns are also unnecessary. 
To hide the unnecessary columns, highlight one starting from the first unneeded column and 
holding “control” click on the other unneeded columns.  Right click on one of them, Go to 
Hide/Unhide Columns -> Hide.  They should disappear from view.  Now there should just be 
Column A which is the Q values, and one column for each of the files imported.  If you want to 
you can name the columns by clicking in the “Long Name” yellow box.  This makes it easier to 
keep track of which column is which sample and concentration. 
Graph the columns as before and change the scales as before. 
When done, the lines should be different in the region between .01 and .1.  What you should 
notice is that the Buffer should be the lowest line, and the concentrations should increase from 
that (shown below).  Example: Buffer<c1p1<c2p3<c3p5.  If the graph shows the low 
concentration as higher than a higher concentration, they were either mislabeled or not 
actually the labeled concentration. 
 
3.  Once the concentrations are determined, the buffer needs to be subtracted from each 
concentration.  From the graph, on the left side there is a small window showing the 
books/graphs/tables that are in the sheet (shown below).  Double click on the book and the 
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table of values should appear again. More columns need to be added to do the subtractions.  
To do this, click “Column” on the toolbar and then “Add new columns”.  Type how many you 
want to add (add enough for each sample concentration, not buffers. Ex. If you loaded 3 
concentrations and 2 buffers, only add 3 new columns) and click OK.   
 
Highlight one of the new columns, right click on it and click “Set Column Values”.  A dialogue 
box will pop up and here you can type a formula for every cell in the column.  Pick one of the 
concentrations and know which buffer needs to be subtracted from it.  In the new box, type: 
 col(x)-.995*col(y) 
where col(x) is the concentration column and col(y) is the buffer column (the column letters are 
at the top of each).  Click ok and the data should fill out the column.  If most or all values in the 
new subtraction column are positive, everything is good and can move on.  If a lot of the values 
are negative, get to the dialogue box again and change the .995 to something lower like .95 or 
.97.  You can also graph that column (changing the axes like before) and seeing when the part 
of the line around .01 is relatively flat.  The area to the left of this is not flat and very jagged, but 
that is ok.  Once the best number is found, this graph can be deleted.   
 
Do this for each of the remaining concentrations (the .995 value can be different for each one, 
as long as most of the values are positive).  It might be helpful to label which column is which 
concentration minus buffer.   
 
4.  Make more new columns.  These columns will be used to create the Guinier plot. The 
Guinier plot is the graph which gives Rg (radius of gyration) for the sample.  Each concentration 
will have its own Guinier, and an extra column needs to be made for the new x axis, so add n+1 
columns where n is number of concentrations. Example: if there are 3 concentrations, add 4 
columns. 
Label the first new column Q^2 and set its value to: 
 col(A)*col(A) 
Then click the next column and set the value to: 
 Ln(col(x)) 
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Where col(x) is the subtraction column of the concentration you want to graph. 
Do this for each of the remaining columns and concentrations.  It might be helpful to label 
these as ln(concentration subtraction) so you know which one is which. 
Highlight the Q^2 column – right click, Set As, X.  This is very important and the data will not 
make sense if this is not done. 
Then graph one of the ln columns, but instead of using line, use Scatter which is the button next 
to line (shown below).  Do not change the axis types this time – it needs to be linear.  Double 
click on the X axis and change “from” to -.002 and change “to” to .02.  This is the Guinier plot 
for the chosen concentration.  
 
 
5.  Now that the Guinier plot has been made, the Rg values need to be calculated using the 
slope of 2 portions of the graph. If the protein in the sample is globular, only find the slope of 
the first region. In this experiment we knew the protein was extended, so we needed two Rg 
values. 
The graph should look something like this 
 
One of the portions that you need the slope from is the area between .010 and .015.  These 
values can be changed, it should just be a relatively flat part on the right side of the graph.  This 
will give you the length in 1 dimension. This is the only region necessary for a globular protein. 
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The other portion you will need to zoom in to see.  To zoom:  On the very far left hand side, 
there is an icon that looks like a magnifying glass with a + inside.  Click on that and drag from 
about .000 to .003.  This zoomed in part will give you the length in another dimension.  To make 
the graph normal again, there is a magnifying glass under the other one with a – inside (shown 
below).  Click that and it should go back to normal. 
 
The easiest way to check the slope quickly is to: Click on “Gadgets” in the toolbar, Quick Fit, 
Linear.  This gives a yellow box that can be moved to show the slope of the line in the box.  For 
a dual domain, the 1st slope should be around 50-70.  The second domain slope should be 
around 500-600.  Don’t go below about .0001 to find slope here.  Use the yellow box to find 
good straight places to take the slope at. 
After finding where you want to take the slope, there is a more comprehensive way which will 
give the residuals of that area. To do this: On the left side where the magnifying glass is, there is 
a button that looks like 2 vertical arrows that are pointing at each other called “Data Selector” 
(shown below).  Click this and drag the lines that appeared on the graph to the point where you 
want to collect the slope.  Then click “Analysis” in the toolbar, Fitting, Linear Fit, Open Dialogue, 
OK.  A table should appear showing the slope of the line you just made.  That table can be 
deleted because it now is a part of the files on the left hand side. 
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To check the residuals on that line, go back to the book by double clicking on it.  At the bottom 
of the sheet, there should be new tabs called FitLinear1 and FitlinearCurve1.  Click on FitLinear1 
and at the bottom there are some graphs called “Residual Plots” – double click on this.  Don’t 
use the other tab.  The upper left graph is the one to look at.  If all of the red dots are randomly 
scattered above and below the line, that data is good (shown below).  If the dots seem to follow 
a pattern such as a trough or a peak, the data is bad and needs to be deleted and done again.  A 
different area of the Guinier plot should be found that has good residuals.  Right click and 
delete the residual tab (you don’t have to delete this tab if you plan on using the residuals in a 
figure), right click and delete the table, and right click on the line on the Guinier and delete if 
necessary. 
 
All things on the left hand side can be renamed to keep it organized by right clicking, and then 
Rename.  To rename the residual tab in the book, right click, then click Name and comments 
and rename it that way. 
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An easy naming convention is concentrationD1 and concentrationD2 to keep the dimensions 
separate. 
Next go back to the Guinier and zoom in to the other dimension and get the slope of that line, 
same process as before. 
Repeat the Guinier plot making, slope finding and residual checking for all other concentrations.  
Record the slope for each dimension of each concentration. 
6.  After all concentrations slopes have been recorded, plug the slope into this formula: 
 (Sqrt(slope*3)) = Rg value 
 Rg value*2 = Distance 
Record these values. 
Repeat for any other samples. 
Below is an example of a Guinier Plot.  The pink areas represent where the slopes were taken.  
The slope values can be seen in the tables to the left of the graph. 
 
 
 
Basic overview of how to get to Guinier plot. 
 
Take the data in average form of each concentration. 
Subtract the buffer from the concentration 
Plot this graph q vs subtraction 
Take the ln of the subtraction 
Plot this graph q^2 vs ln(subtraction) 
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SMD Tutorial and Instructions 
 
Steered Molecular Dynamic Simulation Instructions  
  
 
make a folder: mkdir (name of folder) 
enter into a folder: cd 
list folders: ls 
take contents of file and print to screen: cat 
to move up a folder: ../ 
to remove a folder: rm 
to make sure the simulation is running, type: top 
to see how long it will take, type: cat mdinfo 
 
copy a pdb from the computer to a supercomputer: 
Open the desktop where the .pdb file is located on X11 
to copy this .pdb file into the supercomputer type: 
scp 3435.pdb (supercomputer IP address) 
 
In order to set the conditions for the molecule we must use the program XLeap which will 
neutralize, set parameters, and put in either explicit/implicit solvent. 
This program will basically tell the atoms how to interact: 
 
AMBER: 
EXPLICIT SOLVENT 
**make sure that you have removed the hydrogen atoms in the pdb file beforehand 
 to delete hydrogens in YASARA: Edit > delete > Hydrogens 
 to delete hydrogens in pymol: type- “remove hydrogens” 
to open amber (this will open AMBER 12SB forcefield): 
type: 
 xleap –x –f $AMBERHOME/dat/leap/cmd/leaprc.ff12SB 
type: 
 model=loadpdb “Ig3536GW.pdb” 
 
click: 
> File> Load PDB File (click file and load pdb project that you want to load)  
 
in order to neutralize, type: 
charge model (this will tell you the charge) 
addions model K+ (# ions: how ever many to neutralize) 
addions model Cl-  
 
 in order to put in explicit solvent, type: 
solvateOct model TIP3PBOX 30.0 
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in order to set parameters, type:  
loadamberparams frcmod.ionsjc_tip3p  
 
to save files that you created, type: 
saveamberparm model modelname.prmtop modelname.inpcrd 
 
 
 
FYIà  inpcrd- input coordinates 
input prmtop => Amberfile 
            inpcrd  => Amber7 restart file 
 
close AMBER by typing quit 
 
IMPLICIT SOLVENT 
to open amber (this will open AMBER 12SB forcefield): 
type: 
 xleap –x –f $AMBERHOME/dat/leap/cmd/leaprc.ff12SB 
type: 
 model 
click: 
> File> Load PDB File (click file and load pdb project that you want to load)  
 
to set the default PBRadii mbondi3 
saveamberparm model model name.prmtop modelname.inpcrd 
 
close AMBER by typing quit 
 
Running the Simulation 
IMPLICIT SOLVENT: 
to run the stretch simulation requires 3 steps: 
1. Minimize structure 
2. Equilibrate 
3. Pull 
*these files will be created in emacs: 
some tips:  
 make sure to hit enter after the backslash 
 ntb=0 implies implicit solvent 
 igb=8 gives the forcefield you are using (ff12SB) 
cut=99 which tells the program how many angstroms away each atom can see 
  to save in emacs: control x, control s 
  to exit emacs: control x, control c 
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Minimization: 
type:  
 emacs modelname.in (this is an input file) 
in emacs, type: 
 modelname-equilibration 
 &cntrl 
 imin=1, 
 maxcyc=5000, 
 ncyc=500, 
 ntb =0, 
 igb =8, 
 cut =999, 
 / 
exit emacs 
 
the next step is to start the minimization, this requires a command: 
pmemd.cuda –O –i modelname.in –o modelname.out –c modelname.inpcrd –p 
modelname.prmtop –r modelname-min.rst 
 
If you want to see the molecule in VMD:  
type: 
 vmd modelname.prmtop 
 in VMD: file- new molecule- 
 load prmtop file 
 file rst. file 
 file type: Amber 7 restart 
 
Equilibration: 
 emacs modelname-equil.in 
 model name-equil 
&cntrl 
   irest = 0, ntx = 1, ig=-1, 
 imin=0, ntb=0, 
 igb=8, ntpr= 1000, ntwx=1000 
ntt = 3, gamma_ln = 1.0, 
tempi = 0.0, temp0 = 300.0, 
nstlim = 10000000, dt = 0.002, 
cut =100, 
 ntwr = 2000, 
ntc = 2, ntf = 2, 
ioutfm=1,ntxo=2, 
/ 
Save and quit 
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** If you are starting equil. for the first time (for that model), irest=0 and ntx=1. If restarting 
equil. irest=1 and ntx=5 
 
emacs submit-script.sh (which has been copied into folder) 
at bottom: 
the next step is to start the equilibration, this requires a command: 
pmemd.cuda –O –i modelname-equil.in –o modelname-equil.out –c modelname-min.rst –p 
modelname.prmtop –r modelname-equil.rst –x modelname-equil.mdcrd 
 
to see if equilibration is done: 
 vmd modelname.prmtop 
 file-new molecule 
 prmtop.load .mdcrd file file type: NetCDF, load all at once 
Extensions- Analysis- RMSD trajectory tool 
protein (whole thing) or resid # to # (certain residues) 
check backbone and plot 
align RMSD 
 
Pulling or compression: 
emacs modelname-equil.in 
 model name-equil 
&cntrl 
irest=1,ntx=5, ig=-1 
imin=0, ntb=0 
igb=8, ntpr=1000, ntwx=1000 
ntt=3, gamma_ln=1.0 
tempi=300.0, temp0=300.0 
nstlim=100000000, dt=0.001 
cut=999 
       jar=1 
       ntwr=1000 
      NTC=2, NtF=2 
      ioutfm=1, ntxo=2 
      / 
     &wt type=’DUMPFREQ’,  istep=1000, / 
     &wt type=’END’, / 
    DISANG= dist.RST 
    DUMPAVE = dist_vs_t 
    LISTIN= POUT 
    LISTOUT=POUT 
 
write dist.RST file: 
 For constant velocity: 
 &rst iat=___, r2=___, r2a=___, rk2=____ 
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iat is the two atoms which are being pulled- choose alpha carbon in VMD 
r2 is the starting distance (vmd-hold 2 while clicking both atoms) 
r2a is the final distane 
rk2 is the spring constant 
 
to run the simulation:  
pmemd.cuda –O –i modelname-equil.in –o modelname-pull.out –c modelname-equil.rst –p 
modelname.prmtop –r modelname-pull.rst –x modelname-pull.nc 
 
EXPLICIT SOLVENT: 
 
 
To run stretch simulation: 
5 steps- 
1. Optimize structure (minimize) 
2. Heating calculation 
3. Density- NPT 
4. Equilibration (2days) 
5. Pulling (3-5 days) 
Scripts for each of these input files is written out below.  Or copy it from an old 
file. 
 
some tips:  
 make sure to hit enter after the backslah 
 ntb=1 implies explicit solvent 
 igb=8 gives the forcefield you are using (ff12SB) 
cut=99 which tells the program how many angstroms away each atom can see 
  to save in emacs: control x, control s 
  to exit emacs: control x, control c 
 
 
3435minimization example 
 
type emacs modelname-min.in 
 
 &cntrl 
  imin   = 1, 
  maxcyc = 1000, 
  ncyc   = 500, 
  ntb    = 1, 
  cut    = 10.0 
/ 
 
save this file: file>save as 
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pmemd.cuda –O –i modelname.in –o modelname.out –c modelname.inpcrd –p 
modelname.prmtop –r modelname-min.rst & 
 
 
 
**to make sure the simulation is running, type: top 
to see how long it will take, type: cat mdinfo 
 
 
3435Heating example 
 
type emacs  modelname-heat.in 
 
3435heating 
 &cntrl 
  imin   = 0, 
  irest  = 0, ig=-1, 
  ntx    = 1, 
  ntb    = 1, 
  cut    = 10.0, 
  ntc    = 2, 
  ntf    = 2, 
  tempi  = 0.0, 
  temp0  = 300.0, 
  ntt    = 3, 
  gamma_ln = 1.0, 
  nstlim = 10000, dt = 0.002 
  ntpr = 100, ntwx = 100, ntwr = -500 
ioutfm=1, ntxo=2 
 /  
 
pmemd.cuda -0 –i 3536heat.in –o Ig3536heat.out –c Ig3536-min.rst -p Ig3536-small3.prmtop –r 
Ig3536heat.rst & 
 
Density example 
 
type emacs modelname-density.in 
 
 
3435density 
 &cntrl 
  imin = 0, irest = 1, ntx = 5, 
  ntb = 2, pres0 = 1.0, ntp = 1, 
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  taup = 2.0, 
  cut = 10.0, ntr = 0, 
  ntc = 2, ntf = 2, 
  tempi = 310.0, temp0 = 310.0, 
  ntt = 3, gamma_ln = 1.0, 
  nstlim = 50000, dt = 0.002, 
  ntpr = 500, ntwx = 500, ntwr = 1000, 
ioutfm=1,ntxo=2 
ig=-1 
/ 
 
pmemd.cuda -O -i Ig3536density.in -o Ig3536density.out -c Ig3536heat.rst_500 -p Ig3536-
small3.prmtop -r Ig3536density.rst -x Ig3536density.nc & 
 
Equilibration example 
type emacs modelname-equil.in 
 
Ig3536-equil.in 
&cntrl 
  imin = 0, irest = 1, ntx = 5, 
  ntb = 1, 
  cut = 8.0, ntr = 0, 
  ntc = 2, ntf = 2, 
  tempi = 310.0, temp0 = 310.0, 
  ntt = 3, gamma_ln = 1.0, 
  nstlim = 10000000, dt = 0.002, 
  ntpr = 2000, ntwx = 2000, ntwr = 2000, 
ioutfm=1,ntxo=2, 
ig=-1 
/ 
 
pmemd.cuda -O -i ig3536-equil.in -o Ig3536-equil.out -c Ig3536density.rst -p Ig3536-
small3.prmtop -r Ig3536-equil.rst -x Ig3536-equil.mdcrd & 
 
Pulling or compression example 
 
First make the dist.RST file: 
 
FOR VMD- open vmd by typing “vmd modelname.prmtop” 
load files for prmtop (i.e. vmd test.prmtop) 
In VMD, open  the mdcrd file 
Use NetCDF 
Change stride to 10 and load all at once 
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To run ptraj scripts, you also need this .RST file.  Change the atoms you are pulling, the 
distance between the atoms, and the speed of pulling: 
 
dist.RST 
&rst iat=13,2690, (this number needs to be changed) 
r2=84.36,   (this number needs to be changed) 
r2a=184.36,   (r2+100) 
rk2=0.2,/ 
 
 
Pulling or compression: 
type emacs modelname-equilibration 
 model name-equil 
&cntrl 
irest=1,ntx=5, ig=-1 
imin=0, ntb=1, 
igb=0, ntpr=1000, ntwx=1000 
ntt=3, gamma_ln=1.0 
tempi=300.0, temp0=300.0 
nstlim=100000000, dt=0.002 
cut=8 
       jar=1 
       ntwr=1000 
      NTC=2, NtF=2 
      ioutfm=1, ntxo=2 
      / 
     &wt type=’DUMPFREQ’,  istep=1000, / 
     &wt type=’END’, / 
    DISANG= dist.RST 
    DUMPAVE = dist_vs_t 
    LISTIN= POUT 
    LISTOUT=POUT 
 
 
To run pulling: 
 
pmemd.cuda –O –i Ig3435equilibration –o 3435.pull.out –c 3435-small-equil.rst –p 
3435-small.prmtop –r 3435-small-pull.rst –x 3435-small-pull.nc & 
 
 
to analyze your data, use these ptraj scripts: 
 
ptraj.script.distance 
trajin 3435-small-pull.nc 
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distance l1dist :86 :91 out l1dist.dat 
distance d1dist :5 :85 out d1dist.dat 
distance d2dist :92 :174 out d2dist.dat 
 
cpptraj modelname.prmtop <ptraj.script.distance> distance.out 
 
ptraj.script.angles- 
trajin 3435-small-pull.nc 
angle d1d2ang :5@C,CA,N :86-92@CA,C,N :174@CA,C,N out d1d2ang.dat mass 
dihedral d1d2dihed :5@C,CA,N :77@CA,C,N :106@CA,C,N :163@CA,C,N out d1d2dihed.dat 
mass 
 
cpptraj modelname.prmtop <ptraj.script.angles> angles.out 
 
 
ptraj.script.interactions 
trajin 3435-small-pull.nc 
#Domain-linker contacts 
nativecontacts :5-85 :86-91 writecontacts native-d1l1.dat resout nativeres-d1l1.dat distance 8.0 
out native-d1l1.out first name native-d1l1 byresidue 
nativecontacts :86-91 :92-174  writecontacts native-d2l1.dat resout nativeres-d2l1.dat distance 
8.0 out native-d2l1.out first name native-d2l1 byresidue 
 
#Domain-Domain Contacts 
#quit 
nativecontacts :5-85 :92-174 writecontacts native-d1d2.dat resout nativeres-d1d2.dat distance 
8.0 out native-d1d2.out first name native-d1d2 byresidue 
#map mapout nativemap.dat series seriesout nativeseries.dat 
#run 
#runanalysis lifetime native1[nonnative] out lifenative.dat nosort 
 
cpptraj modelname.prmtop <ptraj.script.interactions> interactions.out 
 
 
EMACS  
Save: control x, control s 
Exit: control x, control c 
 
to get plots 
gnuplot 
plot ‘dist_vs_t’ u 0:4 w l 
plot 'd1d2dihed.dat.mass' u 1:2 w l 
etc. 
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find storage things 
 
ls -ltrh */* | grep ‘[0-9]G ‘ - lists all files more than 1 gig 
 ls = list 
 l = longform 
 t = timestamp 
 r = reverse timestamp 
 h = human 
 grep = search 
 */* = all directories 
 
 
du -sh directory - how the storage is used. 
 du = disk usage 
 s = search 
 h = human 
 
To convert a .nc file to a .pdb file 
 Type emacs nc_convert.in 
 trajin filename.nc  
strip :WAT 
strip :K+ 
strip :Cl- 
trajout  filename.pdb  
 
save this file 
 
then type cpptraj filename.prmtop nc_convert.in 
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